Results 171 to 180 of about 4,268 (199)

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

Lancet, The, 2022
James P Hughes, Sybil G Hosek, Gonasagrie   +2 more
exaly  

Cabotegravir/testosterone cipionate

Reactions Weekly, 2023
openaire   +1 more source

Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteers

British Journal of Clinical Pharmacology, 2022
Michael A. Jacobs, Meiyappan Solaiyappan
exaly  

Cabotegravir, a new option for PrEP

The Lancet Infectious Diseases, 2020
openaire   +2 more sources

Cabotegravir

Reactions Weekly
openaire   +2 more sources

Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men.

Antimicrobial Agents and Chemotherapy, 2022
Biao Zhu, Hongzhou Lu, Kelong Han
exaly  

Understanding of cabotegravir degradation through isolation and characterization of key degradation products and kinetic studies

Journal of Pharmaceutical and Biomedical Analysis, 2021
Robert Roskar, Zdenko Časar, Lidja Kovač   +2 more
exaly  

Chasing the cabotegravir tail: implications for prevention

The Lancet HIV, 2020
openaire   +2 more sources

Cabotegravir/rilpivirine

Reactions Weekly, 2019
openaire   +1 more source

Cabotegravir–rilpivirine treatment initiation in a nonvirologically suppressed patient

AIDS, 2022
Steven K, Barnett, Laura, Armas-Kolostroubis, Michael, Sension, David J, Riedel   +3 more
openaire   +2 more sources